指南与共识

西班牙SEPAR/SEIMC/卫生部结核感染诊治共识

Recommendations on the Diagnosis and Treatment of Tuberculosis Infection: SEPAR/SEIMC/Spanish Ministry of Health Consensus Statement
RSS 订阅 · 指南共识 · 支气管扩张与结核 · 2026-06-09

该共识由SEPAR、SEIMC与西班牙卫生部制定,聚焦结核感染(TBI)筛查与结核预防性治疗(TPT)。推荐对结核进展高危人群筛查TBI,IGRA优于TST,确诊TBI后先排除结核病再行TPT,首选每日异烟肼联合利福平3个月(3HR)。

要点

  • 高危人群应筛查TBI,优先覆盖肺结核接触者、HIV感染者及免疫抑制者
  • IGRA优于TST,无IGRA或需提高敏感性时可用TST
  • 排除结核病后推荐TPT,首选3HR方案

核心结论

  • 对结核进展高危人群应筛查结核感染,排除结核病后推荐结核预防性治疗。
  • 推荐对TBI检测阳性且排除结核病的高危人群开展TPT,并保障依从性与不良反应监测。

研究设计与样本

  • 西班牙SEPAR、SEIMC与西班牙卫生部共同制定的共识声明,发表于Enferm Infecc Microbiol Clin (Engl Ed) 2026年。

主要发现

  • 在西班牙,推荐TPT前须进行TBI检测。
  • TBI检测首选干扰素γ释放试验(IGRA),TST可在无IGRA或需提高诊断敏感性时使用。
  • 采用特异性抗原的新型皮肤试验(TBST)可能发挥重要作用。
  • TBI筛查应覆盖所有从TBI进展为结核病的高危个体,优先肺结核接触者、HIV感染者、免疫抑制者及其他高风险情形。

关键数值与推荐

  • 首选方案为每日异烟肼(H)联合利福平(R)3个月(3HR)。
  • 利福喷汀在西班牙可及后,1个月每日方案(1HP)与3个月每周方案(3HP)亦可使用。

临床怎么用

  • 对高危人群先做TBI检测,阳性者按共识流程排除结核病后启动TPT。
  • 按可及性选择3HR,利福喷汀可及后可考虑1HP或3HP。
  • 实施TPT时须落实依从性保障及药物不良反应监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enferm Infecc Microbiol Clin (Engl Ed). 2026 Jun-Jul;44(6):503037. doi: 10.1016/j.eimce.2025.503037. ABSTRACT All strategies on the pathway to tuberculosis (TB) elimination prioritise, among other measures, addressing tuberculosis infection (TBI), particularly the identification of individuals and population groups who should be candidates for tuberculosis preventive treatment (TPT). In Spain, a TBI test is required before recommending TPT. An interferon-gamma release assay (IGRA) is preferred over the tuberculin skin test (TST), although the latter may be used in settings where IGRAs are not available or when deemed necessary to increase diagnostic sensitivity. On the other hand, new skin tests employing specific antigens (TBST) may play a key role. As a general principle, screening for TBI should include all individuals at high risk for progressing from TBI to TB, as described in this guideline, prioritising pulmonary TB contacts, people living with HIV, immunocompromised individuals and those in other situations associated with an elevated risk of developing TB. Once TBI has been diagnosed in these high-risk groups, the algorithm set out in this guideline should be applied to rule out TB disease. Once TB has been excluded, TPT should be recommended. The preferred regimen is daily isoniazid (H) plus rifampicin (R) for 3 months (3HR). However, once rifapentine becomes available in Spain, both the 1-month daily (1HP) and the 3-month weekly (3HP) regimens combining H and rifapentine (P) may also be used. Finally, measures must be taken to ensure adherence to TPT and to monitor and manage potential drug-related adverse effects. PMID: 42264591 | DOI: 10.1016/j.eimce.2025.503037

来源:指南共识 · 支气管扩张与结核,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 支气管扩张与结核:Recommendations on the Diagnosis and Treatment of Tuberculosis Infection: SEPAR/SEIMC/Spanish Ministry of Health Consensus Statement

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。